Glucocorticoid therapy for gastrointestinal diseases

Bibliography

• Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 2005;365:801-3
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Burmester GR, Straub RH, et al. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011;63(1):1-9
   PubMed Web of Science ®Google Scholar
• Kochhar R, Poornachandra KS. Intralesional steroid injection therapy in the management of resistant gastrointestinal strictures. World J Gastrointest Endosc 2010;2(2):61-8
   PubMedGoogle Scholar
• Schwiebert LA, Beck LA, Stellato C, et al. Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. J Allergy Clin Immunol 1996;97(1):143-52
   PubMed Web of Science ®Google Scholar
• Zen M, Canova M, Campana C, et al. The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 2011;Apr;10(6):305-10
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action [review]. Arthritis Rheum 2004;50:3408-17
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Molina-Infante J. Emerging Therapeutic Strategies for Eosinophilic Esophagitis. Curr Treat Options Gastroenterol 2013;12(1):1-17
   Google Scholar
• van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69(11):1913-19
   PubMed Web of Science ®Google Scholar
• Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf 2007;30(10):861-81
   PubMed Web of Science ®Google Scholar
• Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008;6:165-73
   PubMed Web of Science ®Google Scholar
• Remedios M, Campbell C, Jones DM, Kerlin P. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc 2006;63(1):3-12
   PubMed Web of Science ®Google Scholar
• Arora AS, Perrault J, Smyrk TC. Topical corticosteroid treatment of dysphagia due to eosinophilic esophagitis in adults. Mayo Clin Proc 2003;78:830-5
   PubMed Web of Science ®Google Scholar
• Helou EF, Simonson J, Arora AS. 3-yr-follow-up of topical corticosteroid treatment for eosinophilic esophagitis in adults. Am J Gastroenterol 2008;103(9):2194-9
   PubMed Web of Science ®Google Scholar
• Noel RJ, Putnam PE, Collins MH, et al. Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastroenterol Hepatol 2004;2:568-75
   PubMed Web of Science ®Google Scholar
• Lindberg GM, Van Eldik R, Saboorian MH. A case of herpes esophagitis after fluticasone propionate for eosinophilic esophagitis. Nat Clin Pract Gastroenterol Hepatol 2008;5(9):527-30
   PubMedGoogle Scholar
• Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010;139(5):1526-37. 1537.e1
   PubMed Web of Science ®Google Scholar
• Schroeder S, Fleischer DM, Masterson JC, et al. Successful treatment of eosinophilic esophagitis with ciclesonide. J Allergy Clin Immunol 2012;129(5):1419-21
   PubMed Web of Science ®Google Scholar
• Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008;6(2):165-73
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Degen L, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011;9(5):400-9.e1
   PubMed Web of Science ®Google Scholar
• Netzer P, Gschossmann JM, Straumann A, et al. Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol 2007;19(10):865-9
   PubMed Web of Science ®Google Scholar
• Ramage JI Jr, Rumalla A, Baron TH, et al. A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol 2005;100:2419-25
   PubMed Web of Science ®Google Scholar
• Kochhar R, Makharia GK. Usefulness of intralesional triamcinolone in treatment of benign esophageal strictures. Gastrointest Endosc 2002;56:829-34
   PubMed Web of Science ®Google Scholar
• Pelclová D, Navrátil T. Do corticosteroids prevent oesophageal stricture after corrosive ingestion? Toxicol Rev 2005;24:125-9
   PubMedGoogle Scholar
• Fulton JA, Hoffman RS. Steroids in second degree caustic burns of the esophagus: a systematic pooled analysis of fifty years of human data: 1956-2006. Clin Toxicol (Phila) 2007;45:402-8
   PubMed Web of Science ®Google Scholar
• Camargo MA, Lopes LR, Grangeia Tde A, et al. Use of corticosteroids after esophageal dilations on patients with corrosive stenosis: prospective, randomized and double-blind study. Rev Assoc Med Bras 2003;49:286-92
   PubMedGoogle Scholar
• Mori A, Enweluzo C, Grier D, Badireddy M. Eosinophilic gastroenteritis: review of a rare and treatable disease of the gastrointestinal tract. Case Rep Gastroenterol 2013;7(2):293-8
   PubMedGoogle Scholar
• Wall AJ, Douglas AP, Booth CC, Pearse AG. Response of the jejunal mucosa in adult coeliac disease to oral prednisolone. Gut 1970;11:7-14
   PubMed Web of Science ®Google Scholar
• Kumar PJ, Silk DB, Marks R, et al. Treatment of dermatitis herpetiformis with corticosteroids and gluten free diet: a study of jejunal morphology and function. Gut 1973;14:280-3
   PubMed Web of Science ®Google Scholar
• Vaidya A, Bolanos J, Berkelhammer C. Azathioprine in refractory sprue. Am J Gastroenterol 1999;94:1967-9
   PubMed Web of Science ®Google Scholar
• Brar P, Lee S, Lewis S, et al. Budesonide in the treatment of refractory celiac disease. Am J Gastroenterol 2007;102(10):2265-9
   PubMed Web of Science ®Google Scholar
• Salmasian H, Rohanizadegan M, Banihosseini S, et al. Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation. Cochrane Database Syst Rev 2010;(1):CD005565
   Google Scholar
• McDonald GB, Bouvier M, Hockenbery DM, et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 1998;115(1):28-35
   PubMed Web of Science ®Google Scholar
• Gorard DA, Hunt JB, Payne-James JJ, et al. Initial response and subsequent course of Crohn’s disease treated with elemental diet or prednisolone. Gut 1993;34:1198-202
   PubMed Web of Science ®Google Scholar
• Modigliani R, Mary JY, Simon JF, et al. Clinical, biological and endoscopic picture of attacks of Crohn’s disease: evaluation of prednisolone. Groupe d’Etude Therapeutique des Affectations Inflammatories Digestives. Gastroenterology 1990;98:811-18
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2008;(2):CD006792
   Google Scholar
• Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994;35:360-2
   PubMed Web of Science ®Google Scholar
• Gelbmann CM, Rogler G, Gross V, et al. Prior bowel resections, perianal disease, and a high initial Crohn’s disease activity index are associated with corticosteroid resistance in active Crohn’s disease. Am J Gastroenterol 2002;97:1438-45
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012;107(9):1409-22
   PubMed Web of Science ®Google Scholar
• Papi C, Luchetti R, Gili L, et al. Budesonide in the treatment of Crohn’s disease: a meta-analysis. Aliment Pharmacol Ther 2000;14(11):1419
   PubMed Web of Science ®Google Scholar
• Prantera C, Rizzi M, Cottone M, et al. Beclomethasone dipropionate in Crohn’s ileitis: a randomised, double-blind trial. Dig Liver Dis 2011;43(6):459-64
   PubMedGoogle Scholar
• Lavy A. Triamcinolone improves outcome in Crohn’s disease strictures. Dis Colon Rectum 1997;40:184-6
   PubMed Web of Science ®Google Scholar
• Singh VV, Draganov P, Valentine J. Efficacy and safety of endoscopic balloon dilation of symptomatic upper and lower gastrointestinal Crohn’s disease strictures. J Clin Gastroenterol 2005;39:284-90
   PubMed Web of Science ®Google Scholar
• Ramboer C, Verhamme M, Dhondt E, et al. Endoscopic treatment of stenosis in recurrent Crohn’s disease with balloon dilation combined with local corticosteroid injection. Gastrointest Endosc 1995;42:252-5
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB, The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: american College Of Gastroenterology, practice parameters committee. Am J Gastroenterol 2010;105:501-23
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40(6):775-81
   PubMed Web of Science ®Google Scholar
• Mulder CJ, Fockens P, Meijer JW, et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;Jun;8(6):549-53
   PubMed Web of Science ®Google Scholar
• Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: current management. J Crohns Colitis 2012;6:991-1030
   PubMed Web of Science ®Google Scholar
• Travis SP, Stange EF, Lémann M, et al. European Crohn’s and Colitis Organization (ECCO). European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohn’s Colitis 2008;2(1):24-62
   Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012;143:1218-26
   PubMed Web of Science ®Google Scholar
• Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomized CORE II study. Gut 2013;63(3):433-41
   PubMed Web of Science ®Google Scholar
• Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2003;(4):CD000301
   Google Scholar
• Carter MJ, Lobo AJ, Travis SP, IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl 5):V1-16
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Brand MD, Burmester GR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 1999;58(2):363-8
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Therapeutic implications of non-genomic glucocorticoid activity. Lancet 2000;356(9224):87-9
   PubMed Web of Science ®Google Scholar
• Stange EF, Travis SP, Vermeire S, European Crohn’s and Colitis Organisation (ECCO). European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2(1):1-23
   PubMed Web of Science ®Google Scholar
• Bossa F, Fiorella S, Caruso N, et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol 2007;102(3):601-8
   PubMed Web of Science ®Google Scholar
• Aytac E, Londono JM, Erem HH, et al. Impact of stress dose steroids on the outcomes of restorative proctocolectomy in patients with ulcerative colitis. Dis Colon Rectum 2013;56(11):1253-8
   PubMed Web of Science ®Google Scholar
• Chande N, MacDonald JK, McDonald JW. Interventions for treating microscopic colitis: a Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group systematic review of randomized trials. Am J Gastroenterol 2009;104(1):235-41; quiz 234, 242
   PubMed Web of Science ®Google Scholar
• Miehlke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2002;123(4):978-84
   PubMed Web of Science ®Google Scholar
• Miehlke S, Madisch A, Voss C, et al. Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther 2005;22(11-12):1115-19
   PubMed Web of Science ®Google Scholar
• Stewart MJ, Seow CH, Storr MA. Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2011;9(10):881-90
   PubMed Web of Science ®Google Scholar
• Denton A, Forbes A, Andreyev J, Maher EJ. Nonsurgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database Syst Rev 2002;(1):CD003455
   Google Scholar
• Kochhar R, Patel F, Scharma SC, et al. Radiation-induced proctosigmoiditis: prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. Dig Dis Sci 1991;36(1):103-7
   PubMed Web of Science ®Google Scholar
• Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994;236:619-32
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Rodríguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001;Jun;1;153(11):1089-93
   PubMed Web of Science ®Google Scholar
• Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18(10):1319-28
   PubMed Web of Science ®Google Scholar
• Shigemura T, Nakamura J, Kishida S, et al. Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study. Rheumatology (Oxford) 2011;50(11):2023-8
   PubMed Web of Science ®Google Scholar
• Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141(10):764-70
   PubMed Web of Science ®Google Scholar
• Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol 2007;157(1):142-8
   PubMed Web of Science ®Google Scholar
• Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009;68(7):1119-24
   PubMed Web of Science ®Google Scholar
• Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65(3):285-93
   PubMed Web of Science ®Google Scholar
• Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry 2001;Feb;3(1):17-21
   PubMedGoogle Scholar